STOCK TITAN

[Form 4] DHI Group, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Medpace Holdings (MEDP) – Form 4 insider transaction

Executive VP of Operations Susan E. Burwig filed a Form 4 reporting the sale of 7,500 common shares on 28-Jul-2025. The trade was executed through a previously placed limit order during an open trading window at a weighted-average price of $450.14 (individual trades ranged $450.00-$450.43), yielding gross proceeds of roughly $3.38 million. After the transaction, Burwig’s direct ownership stands at 57,500 shares.

No derivative securities were involved and no additional purchases or dispositions were disclosed. The filing is strictly an ownership update; it contains no financial performance data or forward-looking commentary.

Medpace Holdings (MEDP) – Transazione interna Form 4

La Vicepresidente Esecutiva delle Operazioni, Susan E. Burwig, ha presentato un Modulo 4 segnalando la vendita di 7.500 azioni ordinarie il 28 luglio 2025. L’operazione è stata eseguita tramite un ordine limite precedentemente inserito durante una finestra di trading aperta, ad un prezzo medio ponderato di 450,14 $ (le singole operazioni variavano tra 450,00 $ e 450,43 $), generando proventi lordi di circa 3,38 milioni di dollari. Dopo la transazione, la posizione diretta di Burwig è di 57.500 azioni.

Non sono stati coinvolti strumenti derivati e non sono state segnalate ulteriori compravendite. La comunicazione riguarda esclusivamente un aggiornamento sulla proprietà; non contiene dati sulle performance finanziarie né commenti prospettici.

Medpace Holdings (MEDP) – Transacción interna Formulario 4

La Vicepresidenta Ejecutiva de Operaciones, Susan E. Burwig, presentó un Formulario 4 informando la venta de 7,500 acciones comunes el 28 de julio de 2025. La operación se realizó mediante una orden limitada previamente establecida durante una ventana de negociación abierta, a un precio promedio ponderado de $450.14 (las transacciones individuales oscilaron entre $450.00 y $450.43), generando ingresos brutos aproximados de $3.38 millones. Tras la transacción, la propiedad directa de Burwig se sitúa en 57,500 acciones.

No se involucraron valores derivados ni se revelaron compras o ventas adicionales. La presentación es estrictamente una actualización de propiedad; no contiene datos financieros ni comentarios prospectivos.

Medpace Holdings (MEDP) – Form 4 내부자 거래 신고

운영 부사장인 Susan E. Burwig가 2025년 7월 28일 7,500주 보통주 매도를 보고하는 Form 4를 제출했습니다. 거래는 사전에 설정된 지정가 주문을 통해 개방된 거래 기간 중에 실행되었으며, 가중 평균 가격은 $450.14(개별 거래는 $450.00~$450.43 범위)로, 약 338만 달러의 총 수익을 올렸습니다. 거래 후 Burwig의 직접 보유 주식은 57,500주입니다.

파생상품은 포함되지 않았으며, 추가 매수나 매도는 보고되지 않았습니다. 이번 신고는 소유권 업데이트에 국한되며, 재무 성과 데이터나 미래 전망에 관한 언급은 포함하지 않습니다.

Medpace Holdings (MEDP) – Transaction d’initié Formulaire 4

La Vice-Présidente Exécutive des Opérations, Susan E. Burwig, a déposé un Formulaire 4 rapportant la vente de 7 500 actions ordinaires le 28 juillet 2025. La transaction a été réalisée via un ordre à cours limité préalablement placé durant une fenêtre de négociation ouverte, à un prix moyen pondéré de 450,14 $ (les transactions individuelles variaient entre 450,00 $ et 450,43 $), générant des produits bruts d’environ 3,38 millions de dollars. Après cette opération, la détention directe de Burwig s’élève à 57 500 actions.

Aucun titre dérivé n’a été impliqué et aucun achat ou cession supplémentaire n’a été divulgué. Le dépôt constitue uniquement une mise à jour de propriété ; il ne contient aucune donnée financière ni commentaire prospectif.

Medpace Holdings (MEDP) – Insider-Transaktion Form 4

Die Executive VP of Operations, Susan E. Burwig, reichte ein Form 4 ein und meldete den Verkauf von 7.500 Stammaktien am 28. Juli 2025. Der Handel wurde über einen zuvor platzierten Limitauftrag während eines offenen Handelsfensters zu einem gewichteten Durchschnittspreis von 450,14 $ (Einzeltransaktionen lagen zwischen 450,00 $ und 450,43 $) ausgeführt und erzielte Bruttoerlöse von etwa 3,38 Millionen Dollar. Nach der Transaktion hält Burwig direkt 57.500 Aktien.

Es wurden keine derivativen Wertpapiere gehandelt, und es wurden keine weiteren Käufe oder Verkäufe bekannt gegeben. Die Meldung ist ausschließlich ein Eigentumsupdate und enthält keine finanziellen Leistungsdaten oder zukunftsgerichtete Aussagen.

Positive
  • None.
Negative
  • Executive share sale: EVP Susan Burwig sold 7,500 MEDP shares (~$3.4 M), which investors may perceive as a modest negative signal despite sizeable remaining stake.

Insights

TL;DR: Senior MEDP executive sold ~12% of her direct stake; modest size suggests routine diversification, not a material strategic signal.

The 7,500-share sale represents about 11-12% of Burwig’s reported 65,000-share pre-sale position (assuming no indirect holdings). While $3.4 million is sizeable in absolute terms, she retains 57,500 shares, maintaining meaningful alignment with shareholders. There is no indication of distress, option exercise, or concurrent insider selling cluster. Historically, single insider sales of this magnitude at Medpace have had limited impact on share performance. Therefore, I view the filing as neutral to sentiment.

TL;DR: Transaction executed via limit order during open window, complying with best-practice trading policies; no governance concerns detected.

The disclosure specifies that the trade was effected under a limit order placed in an authorized trading window, suggesting adherence to Medpace’s insider-trading policies. Presence of an attorney-in-fact signature further evidences procedural compliance. No derivative positions, pledging, or 10b5-1 plans were cited. From a governance perspective, this is routine and non-impactful.

Medpace Holdings (MEDP) – Transazione interna Form 4

La Vicepresidente Esecutiva delle Operazioni, Susan E. Burwig, ha presentato un Modulo 4 segnalando la vendita di 7.500 azioni ordinarie il 28 luglio 2025. L’operazione è stata eseguita tramite un ordine limite precedentemente inserito durante una finestra di trading aperta, ad un prezzo medio ponderato di 450,14 $ (le singole operazioni variavano tra 450,00 $ e 450,43 $), generando proventi lordi di circa 3,38 milioni di dollari. Dopo la transazione, la posizione diretta di Burwig è di 57.500 azioni.

Non sono stati coinvolti strumenti derivati e non sono state segnalate ulteriori compravendite. La comunicazione riguarda esclusivamente un aggiornamento sulla proprietà; non contiene dati sulle performance finanziarie né commenti prospettici.

Medpace Holdings (MEDP) – Transacción interna Formulario 4

La Vicepresidenta Ejecutiva de Operaciones, Susan E. Burwig, presentó un Formulario 4 informando la venta de 7,500 acciones comunes el 28 de julio de 2025. La operación se realizó mediante una orden limitada previamente establecida durante una ventana de negociación abierta, a un precio promedio ponderado de $450.14 (las transacciones individuales oscilaron entre $450.00 y $450.43), generando ingresos brutos aproximados de $3.38 millones. Tras la transacción, la propiedad directa de Burwig se sitúa en 57,500 acciones.

No se involucraron valores derivados ni se revelaron compras o ventas adicionales. La presentación es estrictamente una actualización de propiedad; no contiene datos financieros ni comentarios prospectivos.

Medpace Holdings (MEDP) – Form 4 내부자 거래 신고

운영 부사장인 Susan E. Burwig가 2025년 7월 28일 7,500주 보통주 매도를 보고하는 Form 4를 제출했습니다. 거래는 사전에 설정된 지정가 주문을 통해 개방된 거래 기간 중에 실행되었으며, 가중 평균 가격은 $450.14(개별 거래는 $450.00~$450.43 범위)로, 약 338만 달러의 총 수익을 올렸습니다. 거래 후 Burwig의 직접 보유 주식은 57,500주입니다.

파생상품은 포함되지 않았으며, 추가 매수나 매도는 보고되지 않았습니다. 이번 신고는 소유권 업데이트에 국한되며, 재무 성과 데이터나 미래 전망에 관한 언급은 포함하지 않습니다.

Medpace Holdings (MEDP) – Transaction d’initié Formulaire 4

La Vice-Présidente Exécutive des Opérations, Susan E. Burwig, a déposé un Formulaire 4 rapportant la vente de 7 500 actions ordinaires le 28 juillet 2025. La transaction a été réalisée via un ordre à cours limité préalablement placé durant une fenêtre de négociation ouverte, à un prix moyen pondéré de 450,14 $ (les transactions individuelles variaient entre 450,00 $ et 450,43 $), générant des produits bruts d’environ 3,38 millions de dollars. Après cette opération, la détention directe de Burwig s’élève à 57 500 actions.

Aucun titre dérivé n’a été impliqué et aucun achat ou cession supplémentaire n’a été divulgué. Le dépôt constitue uniquement une mise à jour de propriété ; il ne contient aucune donnée financière ni commentaire prospectif.

Medpace Holdings (MEDP) – Insider-Transaktion Form 4

Die Executive VP of Operations, Susan E. Burwig, reichte ein Form 4 ein und meldete den Verkauf von 7.500 Stammaktien am 28. Juli 2025. Der Handel wurde über einen zuvor platzierten Limitauftrag während eines offenen Handelsfensters zu einem gewichteten Durchschnittspreis von 450,14 $ (Einzeltransaktionen lagen zwischen 450,00 $ und 450,43 $) ausgeführt und erzielte Bruttoerlöse von etwa 3,38 Millionen Dollar. Nach der Transaktion hält Burwig direkt 57.500 Aktien.

Es wurden keine derivativen Wertpapiere gehandelt, und es wurden keine weiteren Käufe oder Verkäufe bekannt gegeben. Die Meldung ist ausschließlich ein Eigentumsupdate und enthält keine finanziellen Leistungsdaten oder zukunftsgerichtete Aussagen.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Connolly Edward Jack

(Last) (First) (Middle)
C/O DHI GROUP, INC.
6465 SOUTH GREENWOOD PLAZA, SUITE 400

(Street)
CENTENNIAL CO 80111

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
DHI GROUP, INC. [ DHX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Legal Officer
3. Date of Earliest Transaction (Month/Day/Year)
07/25/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/25/2025 F 1,445(1) D $2.78 99,735 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Reflects the withholding of shares by the Issuer to satisfy tax obligations upon the vesting of a restricted stock award.
Remarks:
/s/ E. Jack Connolly, Attorney-in-Fact 07/29/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Medpace (MEDP) shares did Susan Burwig sell?

The filing reports a sale of 7,500 common shares on 28-Jul-2025.

What price did the MEDP shares sell for?

The weighted-average sale price was $450.14, with individual trades between $450.00 and $450.43.

How many MEDP shares does Susan Burwig still own after the sale?

She directly owns 57,500 shares following the reported transaction.

Were any derivative securities involved in the Form 4 filing?

No. No options, warrants, or other derivatives were reported in this filing.

Does the filing cite a 10b5-1 trading plan?

The filing references a limit order placed during an open trading window; it does not mention a 10b5-1 plan.
Dhi Group Inc

NYSE:DHX

DHX Rankings

DHX Latest News

DHX Latest SEC Filings

DHX Stock Data

129.19M
40.70M
16.98%
65.61%
0.35%
Software - Application
Services-business Services, Nec
Link
United States
CENTENNIAL